



IND-SWIFT LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2025

Date: 13th February 2025

**The President
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001**

**The Vice President,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051**

**ISIN: INE915B01019
BSE Scrip Code: 532305**

NSE Symbol: INDSWFTLAB

Subject: Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024.

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/ 185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 02, 2025, we are submitting herewith the Integrated Filing (Financial) for the quarter and the nine-months ended December 31, 2024.

The same is also being made available on the website of the Company at www.indswiftlabs.com

Kindly take the same on your records.

Thanking you,
For **IND-SWIFT LABORATORIES LTD.**



**PARDEEP VERMA
VP-CORPORATE AFFAIRS &
COMPANY SECRETARY**



RATTAN KAUR & ASSOCIATES
CHARTERED ACCOUNTANTS
SCF: 1, SECTOR: 20-C
CHANDIGARH: 160020
Mobile: 9501343300
Email: carattan@gmail.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to

The Board of Directors
Ind-Swift Laboratories Ltd.
SCO 850, Shivalik Enclave
NAC Manimajra
Chandigarh

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of **Ind-Swift Laboratories Ltd.** ("the Company") for the Quarter and Nine Months ended 31st December 2024 ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 as amended (the "Listing Regulations").
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors in their meeting held on 13th February, 2025 has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules, as amended, read with Circular, issued there under and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of Interim Financial Information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with





RATTAN KAUR & ASSOCIATES
CHARTERED ACCOUNTANTS
SCF: 1, SECTOR: 20-C
CHANDIGARH: 160020
Mobile: 9501343300
Email: carattan@gmail.com

standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rattan Kaur & Associates
Chartered Accountants
(Regd No: 022513N)



Place: Chandigarh
Date: 13.02.2025
UDIN: 25513530BMJOLU3742

Rattan Kaur
(Partner)
M. No. 513530



Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853
 E-mail : info@indswiflabs.com Website : www.indswiflabs.com
 CIN No. L24232CH1995PLC015553




IND SWIFT LABORATORIES LTD.						
Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101						
STATEMENT OF STANDALONE & CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTH ENDED 31ST DEC 2024						
CIN L24232CH1995PLC015553						
	Rs. In Lakhs					
Particulars	STANDALONE					
	Quarter Ended 31.12.2024	Quarter Ended 30.09.2024	Quarter Ended 31.12.2023	Nine Month Ended 31.12.2024	Nine Month Ended 31.12.2023	Year Ended 31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income from Operations:						
Revenue from operations	140.80	270.62	27628.25	3457.03	84558.80	122731.79
Other Income	1381.03	1294.61	711.37	3789.59	2006.36	4531.35
Total Income	1521.83	1565.23	28339.62	7246.61	86565.16	127263.15
EXPENSES:						
a Cost of Materials Consumed	0.00	0.00	15336.44	0.00	43409.77	56117.61
b. Purchase of stock in Trade	36.73	49.85	175.60	2604.41	237.62	2533.24
c. (Increase) /decrease in FG,WIP & stock in trade	0.00	0.00	(942.52)	0.00	(688.77)	3707.27
d. Employee benefit	616.12	521.74	3568.32	1693.52	11038.88	14888.43
e. Finance Costs	11.36	41.08	2105.41	69.31	6257.55	5109.55
f. Depreciation	24.59	21.65	1355.59	71.23	4062.88	5330.28
g. Other expenditure	369.39	898.92	4066.10	1693.72	12815.54	20488.66
TOTAL EXPENSES	1058.18	1533.24	25664.94	6132.19	77133.47	108175.05
Profit(loss) before exceptional Items and Tax	463.65	31.99	2674.68	1114.42	9431.70	19088.09
Exceptional Items (Income) /loss	0.00	0.00	0.00	0.00	0.00	(38659.00)
Profit(loss) before Tax (After exceptional items)	463.65	31.99	2674.68	1114.42	9431.70	57747.09
Tax Expenses :-						
Current Tax	0.00	0.00	467.32	0.00	1647.91	16088.66
Mat credit Utilisation	0.00	0.00	35.98	0.00	897.50	897.50
Deferred Tax	0.00	0.00	0.00	0.00	0.00	(1084.34)
Income Tax Adjustment of Previous Years	0.00	0.00	5.91	0.00	6.25	6.25
Profit/ (Loss) after tax and before share of	463.65	31.99	2165.47	1114.42	6880.04	41839.01
Share of profit (loss) in joint venture	0.00	0.00	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) for the period from continuing operations	463.65	31.99	2165.47	1114.42	6880.04	41839.01
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
Tax Expense of discounting operations	0.00	0.00	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) from discontinuing operations(after Tax)	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit / (Loss) for the period after tax & Exceptional items)	463.65	31.99	2165.47	1114.42	6880.04	41839.01
Other Comprehensive Income						
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00	0.00	0.00
B) items that will be reclassified into P/L A/c	0.00	0.00	0.00	0.00	37.48	34.70
Other Comprehensive Income (Loss) for the period , net of Tax	0.00	0.00	0.00	0.00	37.48	34.70
Total Comprehensive Income for the Period	463.65	31.99	2165.47	1114.42	6842.55	41804.31
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	5908.69	5908.69	5908.69	5908.69	5908.69	5908.69
Reserve excluding revaluation reserves						86315.53
EPS (of Rs. 10/- each) (Not annualised)						
Basic	0.78	0.05	3.66	1.89	11.64	70.81
Diluted	0.78	0.05	3.66	1.89	11.64	70.81

Place: Chandigarh
 Date: 13-02-2025

For Ind Swift Laboratories Ltd

N.R. Munjal
 N.R. Munjal
 Chairman & Managing Director





RATTAN KAUR & ASSOCIATES

CHARTERED ACCOUNTANTS

SCF: 1, SECTOR: 20-C

CHANDIGARH: 160020

Mobile: 9501343300


Email: carattan@gmail.com

Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.

Review Report to

The Board of Directors
Ind-Swift Laboratories Ltd.
SCO 850, Shivalik Enclave
NAC Manimajra
Chandigarh

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results ("the Statement") of **IND-SWIFT LABORATORIES LIMITED** (the "Holding Company") ,its subsidiaries (the Holding company and its subsidiaries together referred to as "the Group") for the quarter & nine months ended 31st December, 2024 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") as amended, read with the relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to



obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 date March 29, 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of:

<u>Particulars</u>	<u>Name of the Company</u>
Subsidiary Companies	Ind Swift Laboratories Inc. USA Fortune (India) Constructions Ltd MJM Remedies Private Limited ISLL Middle East LLC- FZ
Joint Venture	INDIS Healthcare LLP

5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results includes the interim financial statements/financial information/financial results of three subsidiaries which have not been reviewed/audited by their auditors, whose interim financial statements/financial information /financial results reflect total revenue of Rs 725.84 Lakhs and Rs. 1927.86 Lakhs for quarter ended 31.12.2024 and nine months ended 31.12.2024 respectively, total net profit/(loss) before tax of Rs. (571.78) Lakhs and Rs. (1066.19) Lakhs for quarter ended 31.12.2024 and nine months ended 31.12.2024 respectively and total comprehensive income of Rs. (464.19) Lakhs and Rs. (974.17) Lakhs for the quarter ended 31.12.2024 and nine months ended 31.12.2024 respectively as considered in consolidated unaudited financial results.





RATTAN KAUR & ASSOCIATES

CHARTERED ACCOUNTANTS

SCF: 1, SECTOR: 20-C

CHANDIGARH: 160020

Mobile: 9501343300

Email: carattan@gmail.com

7. The consolidated unaudited financial results include the interim financial statements/Financial information/Financial results of INDIS healthcare LLP (Joint Venture) which have been reviewed/audited by the auditors whose interim financial statements /Financial information/ Financial results reflect total Net Profit /(Loss) of Rs. 1.16 Lakhs and Rs. (4.74) Lakhs for quarter ended 31.12.2024 and nine months ended 31.12.2024 respectively.

Accordingly to the information and explanations given to us by the Management, these interim financial statements /financial information/financial results are not material to the Group. Our Conclusion on the Statement is not modified in respect of the above matter.

For Rattan Kaur & Associates

Chartered Accountants

FRN: 022513N



Rattan Kaur

(Partner)

M. No. 513530

Place: Chandigarh

Date: 13.02.2025

UDIN: 25513530BMJOLV9006



Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853
 E-mail : info@indswiflabs.com Website : www.indswiflabs.com
 CIN No. L24232CH1995PLC015553



IND SWIFT LABORATORIES LTD.						
Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101						
STATEMENT OF STANDALONE & CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTH ENDED 31ST DEC 2024						
CIN L24232CH1995PLC015553						
	Rs. In Lakhs					
	CONSOLIDATED					
Particulars	Quarter Ended 31.12.2024	Quarter Ended 30.09.2024	Quarter Ended 31.12.2023	Nine Month Ended 31.12.2024	Nine Month Ended 31.12.2023	Year Ended 31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income from Operations:						
Revenue from operations	866.45	1195.68	28751.43	5378.77	88756.50	128089.99
Other Income	1381.22	1300.52	711.39	3795.70	2011.70	4536.75
Total Income	2247.67	2496.20	29462.82	9174.47	90768.20	132626.74
EXPENSES:						
a Cost of Materials Consumed	585.22	781.39	16310.45	1579.95	46666.12	59905.88
b. Purchase of stock in Trade	36.73	49.85	175.60	2604.41	237.62	2533.24
c. (Increase) /decrease in FG,WIP & stock in trade	0.00	0.00	(942.52)	0.00	(688.77)	3707.27
d. Employee benefit	669.64	580.45	3708.19	1858.75	11356.11	15281.15
e. Finance Costs	11.40	41.12	2105.41	69.40	6257.61	5110.36
f. Depreciation	24.59	21.65	1355.59	71.23	4062.88	5330.28
g. Other expenditure	1028.22	963.38	4330.70	2942.50	13416.95	21241.84
TOTAL EXPENSES	2355.80	2437.83	27043.42	9126.24	81308.53	113110.01
Profit(loss) before exceptional Items and Tax	(108.13)	58.36	2419.40	48.23	9459.67	19516.73
Exceptional Items (Income) /loss	0.00	0.00	0.00	0.00	0.00	(38659.00)
Profit(loss) before Tax (After exceptional Items)	(108.13)	58.36	2419.40	48.23	9459.67	58175.72
Tax Expenses :-						
Current Tax	(107.59)	18.45	424.61	(92.02)	1680.15	16211.14
Mat credit Utilisation	0.00	0.00	35.98	0.00	897.50	897.50
Deferred Tax	0.00	0.00	0.00	0.00	0.00	(1084.34)
Income Tax Adjustment of Previous Years	0.00	0.00	5.91	0.00	6.25	6.25
Profit/ (Loss) after tax and before share of	(0.54)	39.92	1952.89	140.25	6875.77	42145.17
Share of profit (loss) in joint venture	1.16	1.42	(11.01)	(4.74)	(43.95)	(49.01)
Profit (+)/ Loss (-) for the period from continuing operations	0.62	41.34	1941.88	135.51	6831.82	42096.16
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
Tax Expense of discounting operations	0.00	0.00	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) from discontinuing operations(after Tax)	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit /(Loss) for the period after tax & Exceptional Items)	0.62	41.34	1941.88	135.51	6831.82	42096.16
Other Comprehensive Income						
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00	0.00	0.00
B) items that will be reclassified into P/L A/c	0.00	0.00	0.00	0.00	37.48	34.70
Other Comprehensive Income (Loss) for the period , net of Tax	0.00	0.00	0.00	0.00	37.48	34.70
Total Comprehensive Income for the Period	0.62	41.34	1941.88	135.51	6794.34	42061.46
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	5908.69	5908.69	5908.69	5908.69	5908.69	5908.69
Reserve excluding revaluation reserves						95247.83
EPS (of Rs. 10/- each) (Not annualised)						
Basic	0.00	0.07	3.29	0.23	11.56	71.24
Diluted	0.00	0.07	3.29	0.23	11.56	71.24

For Ind Swift Laboratories Ltd

N.R. Munjal
 N.R. Munjal
 Chairman & Managing Director
 CHANDIGARH
 Ind-Swift Laboratories Ltd.

Place: Chandigarh
 Date: 13-02-2025



Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Notes: -

1. The standalone and consolidated unaudited financial results have been prepared considering the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended. These results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 13th February, 2025.
2. The standalone and consolidated financial statements for the quarter ended and nine months ended 31.12.2024 have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
3. Details of amount considered as the exceptional items are as under:

STANDALONE

(Rs. In Lakhs)

Particulars	Quarter ended 31.12.2024	Quarter ended 30.09.2024	Quarter ended 31.12.2023	Nine Months ended 31.12.2024	Nine Months ended 31.12.2023	Year ended 31.03.2024*
Exceptional Items	0.00	0.00	0.00	0.00	0.00	38659.00

CONSOLIDATED

(Rs. In Lakhs)

Particulars	Quarter ended 31.12.2024	Quarter ended 30.09.2024	Quarter ended 31.12.2023	Nine Months ended 31.12.2024	Nine Months ended 31.12.2023	Year ended 31.03.2024*
Exceptional Items	0.00	0.00	0.00	0.00	0.00	38659.00

* An exceptional gain of INR 386.59 Crores as shown in financial year ended 31st March, 2024 was on account of the slump sale of the API and CRAMS Business of the Company.

4. The Company has invested the available surplus funds in various investment avenues which is regularly being monitored by the Investment Committee duly constituted by the Board of Directors of the Company.
5. The consolidated financial results include the financial results of the parent company Ind-Swift Laboratories Limited and the financial results of the following subsidiaries/Joint Venture:
 - a) Ind-Swift Laboratories Inc., USA (Subsidiary)
 - b) Fortune (India) Constructions Limited (Subsidiary)
 - c) Indis Healthcare LLP (Joint Venture)
 - d) MJM Remedies Private Limited (Subsidiary)
 - e) ISLL Middle East LLC-FZ (Subsidiary)

Ind-Swift Laboratories Limited and its subsidiaries are collectively referred to as 'the Group'.

6. No adjustment has been made in respect of Deferred Taxes & Current Tax as per IND AS-12, as the same would be provided at the year end.





Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553




7. During the quarter under review the Company has not issued any Non-Convertible Debt Securities.
8. The Company has filed first Motion Petition for Amalgamation of Ind Swift Limited with Ind Swift Laboratories Ltd. The Hon'ble NCLT, Chandigarh Bench vide their order dated 03.01.2025 approved the first motion application and directed the company to conduct the meeting of Equity Shareholders and Unsecured Creditors which is scheduled to be held on 22nd February, 2025.
9. The previous period figures have been re-grouped and re-classified wherever necessary.
10. The Company is exclusively in the Pharmaceutical Business segment.

Place: Chandigarh
Date: 13th February, 2025

For Ind Swift Laboratories Limited

N.R. Munjal

N.R. Munjal
Chairman & Managing Director





Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920,5061850, 5061853
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



B. STATEMENT OF DEVIATION/VARIATION IN UTILIZATION OF FUNDS UNDER REGULATION 32 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

We hereby state that the preferential issue proceeds of the Company as utilized during the quarter ended 31.12.2024 for the objects of the issue are given hereunder and there was no deviation in utilization of funds from those stated in the letter of offer.

Statement of Deviation or Variation in utilization of funds raised	
Name of listed entity	Ind-Swift Laboratories Limited
Mode of Fund Raising	Preferential Issue of Convertible Warrants
Date of Raising Funds	30.08.2024
Amount Raised	₹ 78.73* Crores out of the total issue size of Rs. 314.60 Crores (approx. 25% of the total issue size)
Report filed for Quarter ended	31.12.2024
Monitoring Agency	Applicable
Monitoring Agency Name	CARE Ratings Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA
If Yes, Date of shareholder Approval	NA
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	No Comments

**Note: A sum of ₹ 8.12 Lakhs is included in the aforesaid amount, which constitutes the excess amount received from one of the allottees, which will be returned in the due course.*

Objects for which funds have been raised and where there has been a deviation, in the following table:

(In ₹ Crore)						
Original Object	Modified Object, if any	Original Allocation (in Crores)	Modified allocation, if any	Funds Utilized (in crores)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Expansion of Business of the Company or the Wholly Owned Subsidiaries	NA	150.00	NIL	7.62	NIL	Out of ₹ 78.73 Crores raised through the preferential issue, a sum of ₹ 57.65 Crores have been utilized towards the objects of the issue.
Investment in existing or to be acquired Subsidiaries	NA	50.00	NIL	-	NIL	



Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Working Capital for existing business	NA	39.60	NIL	-	NIL
General Corporate Purpose	NA	75.00	NIL	50.03	NIL
Total		314.60		57.65	

Deviation or Variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES -

Not Applicable

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS

(applicable only for half-yearly filings i.e., 2nd and 4th quarter) –

Not Applicable for this quarter.

E. STATEMENT ON THE IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH ANNUAL AUDITED FINANCIAL RESULTS

(Standalone and consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) –

Not Applicable for this quarter.

For **IND-SWIFT LABORATORIES LTD.**



PARDEEP VERMA
VP-CORPORATE AFFAIRS &
COMPANY SECRETARY